Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1893 in Non-Obstructive Hypertrophic Cardiomyopathy
NCT06816251Phase 2Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Feb 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HRS-1893 in hypertrophic cardiomyopathy (HCM) (4 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Adverse events at 14 weeks and Incidence of left ventricular ejection fraction < 50% at 14 weeks. Started Feb 2025; status: completed.
02
Drugs
HRS-1893
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06816251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816251.